Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines
- 142 Downloads
Corticosteroid-induced osteoporosis (CIOP) is currently undertreated. Systematic review of the literature revealed that the percentage of patients treated adequately is dependent on study quality. Therefore, it remains unknown whether adherence to the guidelines is really so poor. Five major quality criteria provide the standard for future studies on this scope.
It has recently been stated that the degree of prophylaxis of corticosteroid-induced osteoporosis (CIOP) is low and effort should be put into determining reasons for non-prescribing of preventive agents. The aim of this study was to identify: how many studies adequately audit the prevalent guideline; the longitudinal trends in prevention of CIOP; which patient groups appear to be most undertreated; and which intervention strategies are effective.
We performed a comprehensive search of MEDLINE and systematically recorded the outcomes and quality of published studies, using five major criteria.
Twenty-four studies were included in the analysis. The quality of the included studies was poor (31%) or moderate (37%). There was a longitudinal increase in quality of the studies and percentage of prevention. Multivariable linear regression showed that the quality of the study was the only independent predictor of the prevention rate reported in the study.
The results show undertreatment of CIOP might be due to insufficient quality of the studies rather than poor practice or failure to recognise the right patients. Future interventions should comply with five major quality criteria, and a multifaceted approach is required in order to make an impact on the underprescribing of CIOP prophylaxis.
KeywordsBisphosphonates Corticosteroid Guideline adherence Osteoporosis Prophylaxis Study quality
We thank Roy Stewart (statistician, MSc) for the assistance on the statistical analyses.
Conflicts of interest
Tjongerschans Hospital has received an unrestricted educational grant from Merck Sharp & Dohme.
- 15.Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005Google Scholar
- 21.Naganathan V, Sambrook P (2001) Osteoporosis and fracture risk prevention in long-term glucocorticoid therapy, authors reply. Arch Intern Med 161:1781Google Scholar
- 45.American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 39:1791–1801CrossRefGoogle Scholar
- 46.American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44:1496–1503CrossRefGoogle Scholar
- 49.de Nijs RNJ, Bijlsma JWJ, Geusens P, Laan RFJM, Lems WF, Struijs A, van Staa TP (2002) Round table meeting: Prevention and treatment of glucocorticosteroid induced osteoporosis. Ned Tijdschr Rheumatol 1:12–17Google Scholar
- 56.Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299PubMedCrossRefGoogle Scholar
- 57.Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013PubMedCrossRefGoogle Scholar
- 58.Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211PubMedCrossRefGoogle Scholar
- 59.Merck Sharpe & Dohme. Registration of Alendronate for GIOP. 2006Google Scholar
- 60.Proctor & Gamble. Registration of Risedronate for GIOP. 2006Google Scholar
- 73.National Osteoporosis Society (1998) Guidance on the prevention and management of corticosteroid induced osteoporosis. National Osteoporosis Society, Bath, UKGoogle Scholar
- 74.Royal College of Physicians (1999) Osteoporosis: Clinical guidelines for prevention and treatment. Royal College of Physicians, London, UKGoogle Scholar
- 76.Dolan AL (2007) Greenwich and Bexley guidelines for identification, assessment and management of osteoporosis. GreenwichGoogle Scholar
- 77.Bone and Tooth Society, Royal College of Physicians, National Osteoporosis Society (2002) Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. Royal College of Physicians, London, UKGoogle Scholar